Thieler Law Corp, member of the Investor Attorney Network, is investigating whether certain officers and directors of Aegerion Pharmaceuticals Inc (NASDAQ: AEGR) violated securities laws in connection with certain financial statements.

The investigation seeks to discover if possible claims on behalf of purchasers of the securities of Aegerion Pharmaceuticals Inc (NASDAQ: AEGR) concerning whether a series of statements by Aegerion Pharmaceuticals Inc regarding its business, its prospects and its operations were materially false and misleading at the time they were made.

On May 12, 2016, Aegerion Pharmaceuticals revealed that it has reached preliminary agreements with the Department of Justice and the Securities and Exchange Commission regarding a settlement of ongoing investigations into the Company’s sales activities and disclosures related to JUXTAPID® (lomitapide) capsules. The Company pleaded guilty and will pay $40 million to the Department of Justice and the Securities and Exchange Commission. Aegerion Pharmaceuticals has also agreed to plead guilty to two misdemeanor misbranding violations of the Food, Drug and Cosmetic Act. One count involves marketing of Juxtapid, without full directions for use. A second count involves failure to comply with risk evaluation and mitigation strategies that are used to restrict the distribution of potentially dangerous drugs.

Based in Cambridge, Massachusetts, and founded in 2005 Aegerion Pharmaceuticals Inc develops and commercializes therapies for patients with debilitating rare diseases.

If you purchased shares of Aegerion Pharmaceuticals Inc (NASDAQ: AEGR) you should contact Thieler Law Corp at mail@thielerlaw.com or call +1 (619) 377 - 4324.

Thieler Law Corp

2534 State Street - Suite 406,

San Diego, CA 92101

by

email: mail@thielerlaw.com 

or

telephone at +1 (619) 377 - 4324

or

visit our website http://www.thielerlaw.com/ 

or

Facsimile: +1 (619) 785 – 3185